Abstract Number: 716 • 2012 ACR/ARHP Annual Meeting
Utility of Novel Patient-Reported Outcome Instruments in Predicting Cardiac Involvement and Pulmonary Hypertension in Patients with Systemic Sclerosis
Background/Purpose: Heart involvement in systemic sclerosis (SSc) includes left ventricular systolic and diastolic dysfunction, right ventricular dysfunction, pericardial disease, and pulmonary hypertension. We recently demonstrated…Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting
Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…Abstract Number: 719 • 2012 ACR/ARHP Annual Meeting
Biomarkers of Pulmonary Hypertension in Patients with Scleroderma: A Case-Control Study
Background/Purpose: The objective of this study was to evaluate for an association between various biomarkers and the presence or absence of pulmonary hypertension (PH) in…Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting
Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…Abstract Number: 721 • 2012 ACR/ARHP Annual Meeting
Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis
Background/Purpose: Pulmonary hypertension (PH) is a major complication of systemic sclerosis (SSc). We observed that a significant proportion of our SSc patients with PH as…Abstract Number: 722 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis Associated Pulmonary Hypertension – Is Pulmonary Veno-Occlusive Disease As Common As They Say?
Background/Purpose: Recent reviews have suggested a high prevalence of pulmonary veno-occlusive disease (PVOD) amongst patients with systemic sclerosis (SSc) associated pulmonary hypertension (PH). Interlobular septal…Abstract Number: 723 • 2012 ACR/ARHP Annual Meeting
Renal Dysfunction and Disease Severity in Scleroderma-Associated Pulmonary Arterial Hypertension
Background/Purpose: Renal disease is a common complication of scleroderma (SSc). Isolated reduction in glomerular filtration rate (GFR), a marker of impaired renal function, can occur…Abstract Number: 724 • 2012 ACR/ARHP Annual Meeting
Survival, Hospitalization or Need for Combination Therapy At One Year in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). Although survival has improved with PAH-specific medications in…Abstract Number: 725 • 2012 ACR/ARHP Annual Meeting
The Role of Interleukin-23 in Spondyloarthropathy
Background/Purpose: Spondyloarthropathy is characterized by inflammation and bony pathology at the entheseal insertion of tendons to bone. Recent investigations have converged upon interleukin(IL)-23, demonstrating firstly…Abstract Number: 726 • 2012 ACR/ARHP Annual Meeting
Dynamic in Vivo Imaging of Th17-Mediated Osteoclastic Bone Resorption in Live Bones by Using Intravital Multiphoton Microscopy
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint synovial inflammation and progressive cartilage/bone destruction. Although various kinds of cell types, such…Abstract Number: 727 • 2012 ACR/ARHP Annual Meeting
Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
Background/Purpose: Odanacatib (ODN) is a potent, orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN…Abstract Number: 728 • 2012 ACR/ARHP Annual Meeting
Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey
Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent…Abstract Number: 729 • 2012 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Underlie Racial Disparities in Lupus Nephritis-Induced End-Stage Renal Disease
Background/Purpose: The G1 and G2 coding variants in the apolipoprotein L1 gene (APOL1; G1: a compound missense allele (glycine-342/methionine-384) and G2: an in-frame deletion (deletion…Abstract Number: 730 • 2012 ACR/ARHP Annual Meeting
Disease Modifying Effect of Strontium Ranelate in Experimental Dog Osteoarthritis: Inhibition of Major Catabolic Pathways
Background/Purpose: To assess the disease modifying (DMOA) effect of strontium ranelate (SrRan) under therapeutic conditions on the progression of structural changes and on the major…Abstract Number: 731 • 2012 ACR/ARHP Annual Meeting
A Systems Biology Approach to Elucidating Pathways Active During the Development of Osteoarthritis
Background/Purpose: OA affects the entire joint but most studies have focused on the disease process in a single tissue. In this study, we identified genes…